Sat, Aug 30, 2014, 9:34 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Velti plc Message Board

cash2go 116 posts  |  Last Activity: 12 minutes ago Member since: Feb 8, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • page 26

    As PharmAthene’s damages expert Baliban reported, the license agreement contemplated by the LATS would have apportioned to PharmAthene approximately 70% of the total return from ST-246.

  • Reply to

    Appeal Bond

    by mustyroger Aug 24, 2014 10:03 AM
    cash2go cash2go Aug 28, 2014 2:13 AM Flag

    Two Benefits for Siga Settling this Case,

    * No "Guilty" Verdict. In a trial, there's usually a "guilty" or "not guilty" verdict, but in a settlement the defendant, person or party on the defensive, may not want a record of guilt. Settling a case is a way to pay for a mistake, but not admit wrongdoing (bad faith as defined by Delaware Law is u-g-l-y)

    * Finality. Siga can focus on future contracts, real cash flow (no appeal bond, rising interest debt, legal expenses), significant milestone payment FDA approval

    Siga is in a (lose more situation) if they were to appeal at this stage. Feels like end game and here is how Siga put it in last PR:

    ...the risk that our internal controls will not be effective in detecting or preventing a misstatement in our financial statements, (xv) the risk that some amounts received and recorded as deferred revenue may someday be determined to have been more properly characterized as revenue when received, (xvi) the risk that some amounts received and recorded as deferred revenue ultimately may not be recognized as revenue, (xvii) the risk that any appeal of the post-remand opinion may not be successful and that such post-remand opinion will be upheld in whole or in part, or that an appeal, if any, by SIGA may result in a different, less favorable ruling that could materially and adversely affect the Company, (xviii) the risk that any appeal may result in extended and expensive litigation, (xix) the risk that continued litigation with PharmAthene, Inc. may impede SIGA’s efforts to continue to grow, and (xx) the risk that SIGA may not be able to establish its intended positions or otherwise may not prevail in any further court proceedings.

  • Reply to

    Appeal Bond

    by mustyroger Aug 24, 2014 10:03 AM
    cash2go cash2go Aug 27, 2014 11:24 PM Flag

    Thanks for posting about the possible Appeal Bond. Looks like Siga has more reason to negotiate in good faith and end the court case the Delaware Courts have used to point out Siga's somewhat criminal "bad faith" history.

    Appeal Bond, nice share. One more good reason Siga may be forced to stop legal maneuvers that only serve Perelman and so few Siga shareholders.

  • Reply to

    Siga running up an impressive cash position

    by cash2go Aug 27, 2014 10:59 PM
    cash2go cash2go Aug 27, 2014 11:09 PM Flag

    According to Yahoo Finance Enterprise Value (Aug 28, 2014)3: -23.82M

    Has Wall Street read the remedy from Parsons and placed a bet that Pharmathene's award will resemble LATS terms as Parsons said in his first finding? Siga must be doing some serious negotiating with PharmAthene to stay in the game for future milestone payments and at least one more sizeable order in the next couple of years.

    GLTA, some impressive Wall Street accumulation w/o running up PIP's price.

  • Looking at Siga's 7-31-2014 10Q
    page 2
    June 30, 2014
    Cash and cash equivalents $99,029,327
    Total current assets.............$129,734,471
    Deferred revenue................$188,081,857

    page 6
    The Company received approximately $15.3 million for the delivery and acceptance in July of 115,000 courses.
    * Also
    Completion of initial BARDA contract for $433 million to be completed by first quarter 2015

    Milestone for FDA approval will be worth $50 to $100 million more

    Settle out of court so that there is not a "guilty of bad faith" on their record will only help in pursuing further BARDA contracts. (Remember the Dealware definition of "bad faith")

    Milestone and further contracts I see much more likely following the March 14 2014 approval by FDA for compassionate use in monkeypox, smallpox & adverse reactions to smallpox vaccine (Vaccinia).

    Sizeable tax credits to use at Siga and Pharmathene.

  • Please take all the locations to Canada. We have plenty of good chains that will replace the locations and second rate food.

  • Reply to

    Delaware Supreme: Court May 28 2013

    by cash2go Aug 24, 2014 1:33 AM
    cash2go cash2go Aug 24, 2014 11:46 PM Flag

    profit, looks like the only thing left is the math and how willing the "bad faith" boyz are to hide cash on the books, COG...and risk really pizzing of the courts.

  • Reply to

    Delaware Supreme: Court May 28 2013

    by cash2go Aug 24, 2014 1:33 AM
    cash2go cash2go Aug 24, 2014 11:42 PM Flag

    Chapter 11?
    I'm thinking that would only be a concern if you are long Siga shares.

    Looking at Siga's 7-31-2014 10Q
    page 2
    June 30, 2014
    Cash and cash equivalents $99,029,327
    Total current assets.............$129,734,471
    Deferred revenue................$188,081,857

    page 6
    The Company received approximately $15.3 million for the delivery and acceptance in July of 115,000 courses.
    * Also
    Completion of initial BARDA contract for $433 million to be completed by first quarter 2015

    Milestone for FDA approval will be worth $50 to $100 million more

    Settle out of court so that there is not a "guilty of bad faith" will only help in pursuing further final BARDA contracts. Remember the Dealware definition of "bad faith".

    Milestone and further contracts I see much more likely following the March 14 approval by FDA for compassionate use in monkeypox, smallpox & adverse reactions to smallpox vaccine (Vaccinia). CMX-001 is the only complication and they are jumping through hoops to design a trial so that they can recover from the monkepox trial where all the monkeys died. CMX-001 in actual smallpox trial with primates? My guess is never and at best would be years away. Tecovirimat has the potential for hundreds of millions of more in BARDA payouts. Siga needs to clear the air and put in their full effort at a prosperous future. I really think ASAP makes sense. Chapter 11? For Siga shareholder I hope not.

  • Reply to

    Delaware Supreme: Court May 28 2013

    by cash2go Aug 24, 2014 1:33 AM
    cash2go cash2go Aug 24, 2014 2:04 AM Flag

    page 28

    Under Delaware law, “bad faith is not simply bad judgment or negligence, but rather it implies the conscious doing of a wrong because of dishonest purpose or moral obliquity; it is different from the negative idea of negligence in that it contemplates a state of mind affirmatively operating with furtive design or ill will.

    * Siga needs to settle this case out of court ASAP. "bad faith" negotiations this time....

  • page 42

    PharmAthene also contends that the Vice Chancellor erroneously failed to award PharmAthene its lump­sum expectation damages on the basis that they would be too speculative.114 We do not reach this claim either, because we reverse the Vice Chancellor’s damages award and remand for him to reconsider it in light of this opinion.

    * (bad faith) got Siga slapped with the interest payment. I suspect the negotiations on terms laid out by Parson's will be taken seriously by Siga. "bad faith" again could come with a harsh penalty?

  • cash2go cash2go Aug 21, 2014 11:42 PM Flag

    Tecovirimat must be getting close to FDA approval and a big milestone payment? Siga is going to see another huge payday upon reaching this milestone. This path was well known after the primate trial in 2006, that's why Siga went with the "bad faith" attempt

  • cash2go cash2go Aug 21, 2014 11:37 PM Flag

    more:
    Inclusion Criteria:

    * DoD-affiliated personnel (including US civilian employees, contractors and other US personnel and dependents, as well as allied military forces and local nationals) of any age, not breastfeeding
    * Has been exposed to or infected with orthodox viruses (i.e., variola (smallpox), vaccinia, monkeypox, or cowpox) OR Has developed serious complications from vaccinia vaccination (eg, eczema vaccinatum, progressive vaccinia, generalized vaccinia that is severe or persistent, and select cases of inadvertent inoculation due to severe pain related to mucosal involvement, ocular involvement) resulting from vaccination, secondary transmission, or other exposure
    * Is available for clinical follow-up for duration of the treatment and follow-up period
    * Must be able to swallow capsules

  • found under clinical trials:

    Expanded access is currently available for this treatment.

    ClinicalTrials.gov Identifier:
    NCT02080767
    ((First received: March 4, 2014))

    The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure to orthodox viruses. Monkey Pox or Smallpox

  • Reply to

    Delaware Supreme Court - notes from appeal decision

    by cash2go Aug 21, 2014 2:27 AM
    cash2go cash2go Aug 21, 2014 11:21 PM Flag

    alpha, I have to agree when the DSC used the word furtive along with ill will.

    furtive, I had to look it up:
    adjective
    attempting to avoid notice or attention, typically because of guilt or a belief that discovery would lead to trouble; secretive.

    BARDA did the first deal with Siga because of the extraordinary potency with lack of side effects shown in the antiviral trials for Tecovirimat. BARDA would likely have confirmed more than the $450 million if not for the furtive taste Siga comes with. The ONLY competition is CMX-001 failed to prevent death in a primate trial against (monkey pox), I think it is a stretch to think they will even be allowed an actual smallpox/primate trial. All the above makes me think BARDA will add to the Tecovirimat order somewhere near the original 14 million courses as planned and canceled.

    "Siga's" ill will precedes it and is very well known, no doubt it hampers BARDA dealing with them. Maybe it would be smart to try for a discounted lump sum and handover of Tecovirimat rights to Pharmathene? More wild guessing on my part. More likely, thinking Tecovirimat has millions of more doses coming from BARDA and Siga will not part with it.

  • Reply to

    Looking at Siga's 7-31-2014 10Q

    by cash2go Aug 19, 2014 3:52 PM
    cash2go cash2go Aug 21, 2014 11:52 AM Flag

    Another $60 to $70 million in the pipeline to be delivered by first quarter '15. I think the actual total was mentioned in the yearly or last quarterly.

    Siga should have no problem with a $250 to $300 million lump sum payment. More "bad faith" negotiations would be a disaster for them. Siga & PIP shareholders would have done much better but for the "bad faith" fiasco."The contract award is worth $433 million and includes options that would raise the contract's total value to approximately $2.8 billion, if exercised"

    GLTA

  • Reply to

    Delaware Supreme Court - notes from appeal decision

    by cash2go Aug 21, 2014 2:27 AM
    cash2go cash2go Aug 21, 2014 11:39 AM Flag

    DAMAGES: The Delaware Supreme Court announces new law in this opinion: When the parties have a Type II agreement to negotiate in good faith, and the record supports the trial court’s finding that the parties would have reached an agreement but for the defendant’s bad faith negotiations, the plaintiff is “entitled to recover contract expectation damages.” Slip op. at 37. Expectation damages presuppose that “the plaintiff can prove damages with reasonable certainty.” See footnote 99. Because this is the first time the Delaware Supreme Court clarified this issue of damages, it reversed and remanded for Chancery to reconsider the award of damages in light of this opinion.

    * This is where the lump payment becomes an acceptable solution? Siga really needs to settle out of court and avoid looking worse than they are. There are more BARDA orders coming for a smallpox antiviral and Siga doesn't need a guilty verdict on their record. Siga and PIP are likely having some serious discussions after Parson's last verdict laid out the process for calculating an award. Getting past this stage ASAP and not looking like a shady company should be Siga's goal. And, to do it ASAP as BARDA has been refunded and there is a limited time to fund the next round of orders.

  • Reply to

    Delaware Supreme Court - notes from appeal decision

    by cash2go Aug 21, 2014 2:27 AM
    cash2go cash2go Aug 21, 2014 3:32 AM Flag

    In 2004, Congress passed the Project BioShield Act—a ten-year, $5.6 billion fund .Bioshield would address each of the 4 threat agents, including Bacillus anthraces (anthrax), smallpox virus, botulinum toxins, and radiological/nuclear agents
    2 category A threats, anthrax and smallpox

    There were very high hopes after it was announced ST-246 (an antiviral) in Sept 2006 had stellar results. That was the moment Siga got sellers remorse and ....

  • * ...the court affirmed the trial court’s finding that SIGA acted in bad faith, noting that bad faith “contemplates a state of mind affirmatively operating with furtive design or ill will.”

    * the aggrieved party is entitled to “expectation” or “benefit of the bargain” damages (e.g., lost profits)

  • Reply to

    Best analyst following PharmAthene?

    by cash2go Aug 19, 2014 4:34 PM
    cash2go cash2go Aug 20, 2014 1:01 AM Flag

    " Shouldn't be long folks"? Could be 2 weeks or 6 months is my guess with it being an out of court settlement. The interest cost on $100 million or $500 million....

  • Reply to

    Best analyst following PharmAthene?

    by cash2go Aug 19, 2014 4:34 PM
    cash2go cash2go Aug 19, 2014 5:04 PM Flag

    Looking for an analyst that follows Siga? Haven't seen any, nor any upgrades despite all the cash flowing into their coffers. Strange for Wall Street to miss pumping Siga

    GLTA

VELT
0.06260.0000(0.00%)Dec 13 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.